Drug Profile

Rezpegaldesleukin - Nektar Therapeutics

Alternative Names: IL-2 conjugate; Interleukin-2 conjugate; LY-3471851; NKTR-358; PEG-conjugated rhIL-2; REZPEG - Nektar Therapeutics

Latest Information Update: 08 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nektar Therapeutics
Developer Eli Lilly and Company; Nektar Therapeutics
Class Anti-inflammatories; Antipsoriatics; Interleukins; Polyethylene glycols; Recombinant proteins; Skin disorder therapies
Mechanism of Action Interleukin 2 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Alopecia areata; Atopic dermatitis; Systemic lupus erythematosus
Discontinued Psoriasis; Ulcerative colitis

Most Recent Events

26 Feb 2025 Nektar Therapeutics completes enrolment of patients in phase II REZOLVE-AA clinical trials in Alopecia areata in Poland, Canada and USA (SC) (NCT06340360)
24 Feb 2025 Nektar Therapeutics plans a phase II trial for Type 1 diabetes mellitus
10 Feb 2025 Nektar therapeutics receives fast track desgination for Atopic dermatitis in USA

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com